Commentary: PET poised to alter the current paradigm for response assessment of non-Hodgkin's lymphoma.
Guermazi
A
A
Synarc Inc. and University of California, San Francisco, CA 94105, USA.
Juweid
M E
ME
D019788:Fluorodeoxyglucose F18; D005710:Gallium Radioisotopes; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000628:therapy; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D018365:Neoplasm, Residual / Q000000981:diagnostic imaging* / Q000628:therapy; D049268:Positron-Emission Tomography; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18